Loading...
01/10 16:00
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several challenges: flat gross profit, declining EBITDA and EPS, high medical costs, canceled orders, increased legal expenses, and volatile margins. The absence of a share repurchase program and macroeconomic uncertainties add to the concerns. Although healthcare and school revenue show growth, the overall sentiment is negative due to financial difficulties and risks. The Q&A reveals high tax rates and management's avoidance of specific impact details, further dampening sentiment. The negative aspects outweigh the positives, leading to a likely negative stock price reaction.
Consolidated Gross Profit Q4 2024 $21.6 million, flat compared to Q4 2023. Fiscal 2024 gross profit was $79.8 million, up from $76.7 million in fiscal 2023.
Adjusted EBITDA Q4 2024 $6.3 million, down from $8.9 million in Q4 2023. Fiscal 2024 adjusted EBITDA was $25.9 million, down from $26.6 million in fiscal 2023.
Adjusted EPS Fiscal 2024 $2.03, down from $2.04 in fiscal 2023.
Engineering Gross Profit Q4 2024 $5.2 million, down from $6.1 million in Q4 2023. Fiscal 2024 gross profit was $22.5 million, up from $20.6 million in fiscal 2023.
Engineering Gross Margin Q4 2024 19.7%, down from 27.0% in Q4 2023. Fiscal 2024 gross margin was 23.4%, down from 24.3% in fiscal 2023.
IT, Life Sciences and Data Solutions Gross Profit Q4 2024 $3.9 million, down from $4.5 million in Q4 2023. Fiscal 2024 gross profit was $14.7 million, down from $16.2 million in fiscal 2023.
IT, Life Sciences and Data Solutions Gross Margin Q4 2024 40.0%, up from 38.7% in Q4 2023. Fiscal 2024 gross margin was 37.5%, down from 38.2% in fiscal 2023.
Health Care Gross Profit Q4 2024 $12.5 million, up from $11.0 million in Q4 2023. Fiscal 2024 gross profit was $42.5 million, up from $39.9 million in fiscal 2023.
Health Care Gross Margin Q4 2024 30.0%, up from 29.8% in Q4 2023. Fiscal 2024 gross margin was 29.8%, up from 29.3% in fiscal 2023.
School Revenue Q4 2024 $34.9 million, up from $29.8 million in Q4 2023.
Non-School Revenue Q4 2024 $6.2 million, down from $6.9 million in Q4 2023. Adjusted for a long-term care group reduction, revenue would be $5.6 million in 2024 versus $5.5 million in Q4 2023.
Days Sales Outstanding (DSOs) 92 DSOs for Q4 2024, improved from 114 DSOs in Q3 2023.
New Product Launches: Thermal Kinetics has successfully designed and launched a new plant expansion program primarily focused on the ethanol industry, resulting in an equipment order for $3.5 million.
Behavioral Health Services: Surging demand for behavioral health services in schools has positioned RCM as a leader in addressing this critical need.
Novel Solution Chemistry Development: Thermal Kinetics has completed an Engineering order to develop novel solution chemistry for a planned lithium facility in the U.S.
Market Expansion in K-12: RCM Health Care is experiencing growth in existing school district partnerships and has a robust pipeline of new school districts and clients.
Energy Services Expansion: Energy Services has secured a third EPC project in Europe and is negotiating several new projects.
Aerospace & Defense Growth: Aerospace & Defense group has increased headcount by 20% in Q4 2024 and expects continued growth through new multiyear contracts.
Operational Efficiencies in Managed Services: Q4 managed services growth reflects cost savings measures, including offshore delivery and productivity tools.
Improved Trade Accounts Receivables: DSOs improved from 114 to 92, indicating better management of trade accounts receivables.
Strategic Shift to AI and ML: 2025 will see a shift from traditional IT services to deployment of AI and ML tools for process automation.
Focus on Behavioral Health: Schools are prioritizing mental and behavioral health support, leading to increased demand for specialized providers.
Macroeconomic Uncertainty: The company is navigating through a period of increased macroeconomic uncertainty, which poses risks to business operations and growth.
High Medical Costs: Abnormally high medical costs related to the self-insured medical plan increased SG&A expenses by approximately $1.25 million.
Canceled Orders: A significant industrial process equipment order was abruptly canceled midway through the project, resulting in a $900,000 reduction in gross profit.
Legal Expenses: Increased legal fees and settlement costs from a class action lawsuit regarding California wages added about $450,000 in SG&A expenses.
Accounts Receivable Issues: A large school client stopped payment due to administrative issues, leading to an estimated $6 million accounts receivable balance exceeding normalized levels. Another client in IT, Life Sciences, and Data Solutions also stopped payments, with an estimated $3.8 million accounts receivable balance exceeding normalized levels.
Volatile Gross Margins: Engineering gross margins were very low due to a high mix shift of lower-margin work and other expenses, with expectations of volatility in future margins.
Strategic Initiatives: The fourth quarter demonstrated strong top line momentum as many of our strategic initiatives gained traction. The company is witnessing a resumption of growth in hours and increasing activity throughout most of the business.
Growth in K-12 Services: A key driver of growth has been the surging demand for behavioral health services in schools, with RCM positioned as a leader in addressing this critical need.
Corrections Clients: The corrections sector demonstrated impressive growth in 2024, with expectations for further expansion in the year ahead.
Energy Services: Energy Services demonstrated robust annual growth, with ongoing negotiations for large-scale projects including grid modernization and data center developments.
Aerospace & Defense: The Aerospace & Defense group continued to win business on new programs, resulting in a 20% increase in headcount in Q4 2024.
2025 Revenue Expectations: The company anticipates double-digit growth on adjusted EBITDA for fiscal 2025.
Gross Margin Expectations: Engineering gross margins are expected to land between 24.0% and 28.0%.
DSO Goals: The goal for Days Sales Outstanding (DSOs) is to get under 80 by the end of fiscal 2025.
Client Growth: The company expects to solidify additional clients and program wins in 2025.
Financial Projections: The company will provide more guidance as the year progresses, with another call scheduled in May.
Share Repurchase Program: RCM Technologies has not announced any share repurchase program during the call.
The earnings call reveals mixed performance: strong growth in school revenue and engineering gross profit, but declines in non-school revenue and life sciences gross profit. Margins are mixed, with some improvement but also declines. The Q&A highlights uncertainties, like visa issues for foreign candidates and persistent high medical costs. Despite optimistic long-term guidance, immediate concerns and lack of clear execution details temper positive sentiment. Without a market cap, a neutral prediction accounts for these balanced positives and negatives.
The earnings call presented a mix of positive and negative elements. Revenue growth and strategic expansions are promising, particularly in engineering and healthcare sectors. Despite some revenue declines and delayed cash flows, the company maintains strong gross margins and cash flow recovery. The Q&A section revealed positive analyst sentiment towards strategic partnerships and market positioning. Although immigration challenges and lack of clear dividend plans pose risks, the overall outlook, including optimistic growth projections and strategic market positioning, suggests a positive stock price movement over the next two weeks.
The earnings call reveals strong financial performance with increased gross profit, EBITDA, and EPS. Positive growth in K-12 services and aerospace sectors, alongside reduced net debt and improved cash flow, indicate robust operational health. Despite some margin variability, guidance remains optimistic. The share repurchase plan further supports stock price appreciation. The Q&A section didn't reveal significant risks, supporting a positive outlook. However, lack of specific guidance and margin concerns temper expectations, placing the prediction in the 'Positive' range (2% to 8%).
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
